Literature DB >> 26748932

Prognostic Factors for Chronic Lymphocytic Leukemia.

Christopher Chen1, Soham Puvvada2.   

Abstract

As novel strategies for treatment and prognostication of chronic lymphocytic leukemia (CLL) evolve, the traditional Rai and Binet systems can now be updated with more modern prognostic markers. This is a review of the latest articles which combine studies from major CLL centers to summarize major prognostic factors for patients diagnosed with CLL. The prognostic information can be categorized into three categories: genetic abnormalities which include 17p, 11q, and immunoglobulin heavy chain variable (IGHV) abnormalities; biochemical abnormalities and cell surface markers which include serum thymidine kinase, β-2-microglobulin, CD49d, CD38, and ZAP-70 levels; and patient characteristics which include sex, age, and performance status.

Entities:  

Keywords:  Chronic lymphocytic leukemia; Prognostication; Treatment

Mesh：

Substances：

Year:  2016        PMID： 26748932     DOI： 10.1007/s11899-015-0294-x

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  44 in total

1.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

2.  Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases.

Authors:  Massimo Gentile; Francesca R Mauro; Davide Rossi; Iolanda Vincelli; Giovanni Tripepi; Anna G Recchia; Laura De Stefano; Melissa Campanelli; Diana Giannarelli; Sabrina Bossio; Lucio Morabito; Ernesto Vigna; Gianluca Gaidano; Robin Foà; Fortunato Morabito
Journal:  Br J Haematol       Date:  2014-07-11       Impact factor: 6.998

3.  The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Authors:  Jennifer R Brown; Jacqueline C Barrientos; Paul M Barr; Ian W Flinn; Jan A Burger; Anh Tran; Fong Clow; Danelle F James; Thorsten Graef; Jonathan W Friedberg; Kanti Rai; Susan O'Brien
Journal:  Blood       Date:  2015-03-09       Impact factor: 22.113

4.  Localization of gene for human p53 tumour antigen to band 17p13.

Authors:  M Isobe; B S Emanuel; D Givol; M Oren; C M Croce
Journal:  Nature       Date:  1986 Mar 6-12       Impact factor: 49.962

5.  Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.

Authors:  Douglas E Gladstone; Lode Swinnen; Yvette Kasamon; Amanda Blackford; Christopher D Gocke; Constance A Griffin; Javier Bolanos Meade; Richard J Jones
Journal:  Leuk Lymphoma       Date:  2011-08-18

6.  CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.

Authors:  Tait D Shanafelt; Susan M Geyer; Nancy D Bone; Renee C Tschumper; Tom E Witzig; Greg S Nowakowski; Clive S Zent; Tim G Call; Betsy Laplant; Gordon W Dewald; Diane F Jelinek; Neil E Kay
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

7.  CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.

Authors:  Pietro Bulian; Tait D Shanafelt; Chris Fegan; Antonella Zucchetto; Lilla Cro; Holger Nückel; Luca Baldini; Antonina V Kurtova; Alessandra Ferrajoli; Jan A Burger; Gianluca Gaidano; Giovanni Del Poeta; Chris Pepper; Davide Rossi; Valter Gattei
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

8.  PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.

Authors:  Martin Weisser; Ru-Fang Yeh; Guillemette Duchateau-Nguyen; Giuseppe Palermo; Tri Quang Nguyen; Xiaoyan Shi; Susanna Y Stinson; Nancy Yu; Annika Dufour; Tadeusz Robak; Galina N Salogub; Anna Dmoszynska; Philippe Solal-Celigny; Krzysztof Warzocha; Javier Loscertales; John Catalano; Loree Larratt; Viktor A Rossiev; Isabelle Bence-Bruckler; Christian H Geisler; Marco Montillo; Kirsten Fischer; Anna-Maria Fink; Michael Hallek; Johannes Bloehdorn; Raymonde Busch; Axel Benner; Hartmut Döhner; Nancy Valente; Michael K Wenger; Stephan Stilgenbauer; David Dornan
Journal:  Blood       Date:  2014-06-10       Impact factor: 22.113

9.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene.

Authors:  G Matlashewski; P Lamb; D Pim; J Peacock; L Crawford; S Benchimol
Journal:  EMBO J       Date:  1984-12-20       Impact factor: 11.598
View more
  7 in total

1.  Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).

Authors:  Neda Alrawashdh; Joann Sweasy; Brian Erstad; Ali McBride; Daniel O Persky; Ivo Abraham
Journal:  Ann Hematol       Date:  2021-07-19       Impact factor: 3.673

Review 2.  Prognostic Factors in the Era of Targeted Therapies in CLL.

Authors:  Prajwal Boddu; Alessandra Ferrajoli
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952

3.  Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China.

Authors:  Heng Li; Wenjie Xiong; Huimin Liu; Shuhua Yi; Zhen Yu; Wei Liu; Rui Lyu; Tingyu Wang; Dehui Zou; Zengjun Li; Lugui Qiu
Journal:  Chin J Cancer Res       Date:  2017-04       Impact factor: 5.087

Review 4.  Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases.

Authors:  Christos P Argyropoulos; Shan Shan Chen; Yue-Harn Ng; Maria-Eleni Roumelioti; Kamran Shaffi; Pooja P Singh; Antonios H Tzamaloukas
Journal:  Front Med (Lausanne)       Date:  2017-06-15

5.  Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.

Authors:  Emilia Białopiotrowicz; Patryk Górniak; Monika Noyszewska-Kania; Bartosz Puła; Hanna Makuch-Łasica; Grażyna Nowak; Aleksandra Bluszcz; Maciej Szydłowski; Ewa Jabłonska; Karolina Piechna; Tomasz Sewastianik; Anna Polak; Ewa Lech-Marańda; Bożena K Budziszewska; Maja Wasylecka-Juszczyńska; Katarzyna Borg; Krzysztof Warzocha; Wojciech Czardybon; Michał Gałęzowski; Renata Windak; Krzysztof Brzózka; Przemysław Juszczyński
Journal:  J Cell Mol Med       Date:  2018-04-17       Impact factor: 5.310

6.  3D-STED Super-Resolution Microscopy Reveals Distinct Nanoscale Organization of the Hematopoietic Cell-Specific Lyn Substrate-1 (HS1) in Normal and Leukemic B Cells.

Authors:  Marta Sampietro; Moreno Zamai; Alfonsa Díaz Torres; Veronica Labrador Cantarero; Federica Barbaglio; Lydia Scarfò; Cristina Scielzo; Valeria R Caiolfa
Journal:  Front Cell Dev Biol       Date:  2021-06-30

7.  Characteristics of chronic lymphocytic leukemia in Senegal.

Authors:  Abibatou Sall; Awa Oumar Touré; Fatimata Bintou Sall; Moussa Ndour; Seynabou Fall; Abdoulaye Sène; Blaise Félix Faye; Moussa Seck; Macoura Gadji; Tandakha Ndiaye Dièye; Claire Mathiot; Sophie Reynaud; Saliou Diop; Martine Raphaël
Journal:  BMC Hematol       Date:  2016-04-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.